



## Senti Biosciences Announces Dr. Laurent Fischer as New Independent Board Member

*Leading gene circuit company taps veteran biotech executive for board of director position to help steward company growth, develop its integrated drug development capabilities, and guide business strategy*

**South San Francisco, June 12, 2019** – Senti Biosciences, the leading gene circuit company focused on outsmarting complex diseases with more intelligent medicines, today announced that Dr. Laurent Fischer has joined the company as an independent member of its board of directors.

"We are excited to have Laurent join us as an independent board member. He has spent his career as a physician, drug developer and entrepreneur, and brings a wealth of experience to the Senti team," said Dr. Tim Lu, CEO of Senti Biosciences. "Laurent's technical expertise and business experience in translating advanced therapies into the clinic will be critical as we move toward human trials."

"I'm thrilled to be part of a company that creates smarter therapies that could transform patients' lives," said Dr. Fischer. "Senti Biosciences is unique in that it designs gene circuits and programs cells to respond, adapt, and make decisions, which could potentially provide tremendous therapeutic value for patients suffering from complex diseases."

Dr. Fischer is currently senior vice president and head of the liver therapeutic area at Allergan, and is also a senior advisor on the Frazier Healthcare Partners' Life Sciences team. Dr. Fischer has more than 20 years of drug development and commercialization experience in the biopharmaceutical industry. He was previously CEO of Tobira Therapeutics, which was acquired by Allergan for up to \$1.7 billion in 2016.

Prior to Tobira, Dr. Fischer was chairman and CEO of Jennerex, Inc., a company with a first-in-class oncolytic immunotherapy acquired for \$150 million by Sillajen. Prior to Jennerex, he was co-founder, president and CEO of Ocera Therapeutics. Dr. Fischer has also held senior positions at DuPont-Merck, DuPont Pharmaceuticals, and Hoffmann-La Roche in liver disease, virology and oncology. He launched Sustiva®, the first once-daily anti-HIV and the 10th top-prescribed specialty drug, in 2015, and was involved in the launch of the first protease inhibitor in the United States. Dr. Fischer received his undergraduate degree from the University of Geneva and his medical degree from the Geneva Medical School, Switzerland.

### About Senti Biosciences

Senti Biosciences is a next-generation therapeutics company that is developing gene circuits and programming cells for tremendous therapeutic value. Our mission is to outsmart complex diseases with more intelligent medicines that will transform people's lives. By programming cells to respond, adapt and make decisions, we are creating smarter therapies with computer-like logic, enhanced functionality and greater therapeutic control. Senti Biosciences is based in South San Francisco and was founded in 2016 by Drs. Tim Lu, Philip Lee, Jim Collins and Wilson Wong. Senti is proud to count NEA, 8VC, Amgen Ventures, Pear Ventures, Lux Capital, Menlo Ventures, Pear Ventures, Allen & Company, Nest.Bio, Omega Funds, Goodman Capital, and LifeForce Capital among their investors. For more information on Senti Biosciences, please visit <https://www.sentibio.com/>.

### Contact

Curt Herberts  
CFO and CBO  
650-906-1674  
[press@sentibio.com](mailto:press@sentibio.com)